TGen's Von Hoff Honored by the University of Michigan Cancer
Center
Presents Third Annual Frances E. Bull Lecture
December 3, 2003
Dr. Daniel D. Von Hoff, Director of TGen's Translational Drug Development Division, Head of its Pancreatic Cancer Research Program, Director of Arizona Health Sciences Center's Cancer Therapeutics Program, and Professor in the Department of Medicine, Molecular and Cellular Biology, and Pathology, University of Arizona College of Medicine, Tucson, Arizona, recently received the Frances E. Bull award from the University of Michigan's Comprehensive Cancer Center and the Division of Hematology/Oncology.
This award, given annually, recognizes a distinguished leader in the field of medical oncology to honor Emeritus Professor Frances Bull, the Cancer Center's first medical oncologist.
Robert Todd, III, MD, PhD, Division of Hematology and Oncology at the University of Michigan Medical Center, introduced this years lecture.
Dr. Von Hoff delivered the Bull Lecture on the topic of "Pursuing Therapeutic Drug Development Targets That Are Not There." He discussed a new strategy for attacking cancer cells. This strategy takes advantage of the fact that cancer cells (but not normal cells) have missing, or deleted, genes that can make them more vulnerable to new therapies. The diversity of these missing genes (or targets that are not there) has been made also possible by genomic research, such as the kind carried out at TGen. "I am delighted to have been selected to receive this award," said Dr. Von Hoff. "Dr. Bull has been a pioneer in the development of new therapies and a role model for multiple young, as well as experienced investigators. She was one of the first to show us some cancers can be cured."
Dr. Von Hoff has authored more than 484 papers, 122 book chapters, and 822 abstracts. He has served as Editor of Molecular Cancer Therapeutics, and has served on 12 editorial boards of peer-reviewed journals including Cancer Research and Annals of Oncology. He has trained over 36 postgraduate fellows. He was a Fellow of the American College of Physicians.
He is the recipient of numerous awards and honors. Most recently, in addition to the Bull Award, he is the recipient of the 2003 Block Award, presented by Ohio State University and The Weinberg Award, presented by the Dana Farber Cancer Center, Harvard Medical School.
About TGen
The mission of the Translational Genomics Research Institute
(TGen) is to make and translate genomic discoveries into advances
in human health. "Translational genomics research" is a relatively
new field employing innovative advances arising from the Human
Genome Project to apply to the development of diagnostics,
prognostics and therapies for cancer, neurologic disorders,
diabetes and other complex diseases.
